BioPharmChina

BioPharmChina(dot)Com is a dedicated news and information portal covering the rapidly evolving biotechnology and biopharmaceutical industry in China

[BioPharmChina @Biopharm_China]

🇨🇳Forlong Biotech’s Pre-B Financing Reaches Nearly RMB 200 Million as It Prepares FL115 for Phase 3 Bladder Cancer Trial https://t.co/N4lCN4kYVU #BioPharmChina #ChinaBioTech #ChinaPharma #CancerTreatment #BladderCancer

[BioPharmChina @Biopharm_China]

ByteDance’s AI Drug Discovery Spinout 🇨🇳Anew Labs Reportedly Raises $290 Million https://t.co/VBK36YPg2c #BioPharmChina #ChinaBioTech #ChinaPharma #AI #DrugDiscovery

[BioPharmChina @Biopharm_China]

🇨🇳Medinno Raises More Than RMB 200 Million to Advance Topical Drug for Diabetic Foot Ulcers https://t.co/5Mrd7ff6xF #BioPharmChina #ChinaBioTech #ChinaPharma #Diabetes @ChineseBiotech

[BioPharmChina @Biopharm_China]

@DavidVanKnapp11 STOCK

[Samuel Hume @DrSamuelBHume]

The world’s first bispecific antibody-drug conjugate was recently approved (in China) and it is EVERYWHERE.

It binds both EGFR and HER3 (not HER2!) which are often co-expressed on the cell surface.

The bispecific design means it binds with more avidity: it's harder to detach, promotes receptor clustering, and improves delivery of the payload. Cells with low EGFR can also be captured through HER3.

It's approved in China for nasopharyngeal carcinoma and esophageal squamous-cell carcinoma, with positive readouts in triple negative breast cancer and lung cancer - and ongoing trials in a spectrum of other cancer types.

BMS owns the rest-of-world rights, and is now taking this global.

[BioPharmChina @Biopharm_China]

@Michael54866170 @DrSamuelBHume Please follow us for latest news and development in China’s biotech and pharma industry. #Biophamchina @Biopharm_China

[AllAboutChina @jackenzheng]

Check out my latest article: List of Speakers at the 29th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) https://t.co/RmFKnIhOD8 来自 @LinkedIn

[BioPharmChina @Biopharm_China]

RemeGen and AbbVie’s RC148 Delivers 90% Response Rate in a Phase 1b Trial of First-Line Squamous NSCLC https://t.co/Jzi9LESrSA #BioPharmChina #ChinaBioTech #ChinaPharma #WCLC2026 #LungCancer #NSCLC @OncologyTimes @oncologytube

[BioPharmChina @Biopharm_China]

BioNTech and OncoC4’s Gotistobart Nearly Doubles Survival in Previously Treated Squamous NSCLC https://t.co/TOFV6jKh01 #BioPharmChina #ChinaBioTech #ChinaPharma #WCLC2026 #LungCancer @OncologyTimes @OncoAlert @oncologytube

[BioPharmChina @Biopharm_China]

Novartis Acquires Global Rights to Sironax Brain-Delivery Platform for $125 Million https://t.co/O2JeWjfflI #BioPharmChina #ChinaBioTech #ChinaPharma

[BioPharmChina @Biopharm_China]

GSK Returns to Chimagen for Multiple Myeloma T-Cell Engager in Deal Worth Up to $750 Million https://t.co/ykR7lKlOYf #BioPharmChina #ChinaBioTech #ChinaPharma #ChinaUSPartnerships

[BioPharmChina @Biopharm_China]

@Word213414 System

[BioPharmChina @Biopharm_China]

Roche and MediLink’s Tam-Peli Cuts Death Risk by 54% in Phase 3 Small-Cell Lung Cancer Trial https://t.co/0v48UN7ncN #BioPharmChina #ChinaBioTech #ChinaPharma #WCLC2026 #LungCancer

[BioPharmChina @Biopharm_China]

Biokin’s Iza-Bren Shows Activity in Previously Treated EGFR-Mutated Lung Cancer, Supports Global Registrational Dose https://t.co/Hb2mhldxd4 #BioPharmChina #ChinaBioTech #ChinaPharma #WCLC2026 #LungCancer #NSCLC #SCLC #CancerResearch

[BioPharmChina @Biopharm_China]

GSK and 🇨🇳Hansoh’s Ris-Rez Cuts Risk of Death by 54% in Phase 3 Small-Cell Lung Cancer Trial https://t.co/6RrtHb1cbz #BioPharmChina #ChinaBioTech #ChinaPharma #ADC #SCLC #LungCancer #CancerTreatment

[BioPharmChina @Biopharm_China]

2026 China Healthcare Decision-Makers Conference (CHDC) https://t.co/YZuQs0doUN #BioPharmChina #ChinaBioTech #ChinaPharma #GlobalPharma Meet you all in Beijing this Oct.

[BioPharmChina @Biopharm_China]

1cBio Licenses PARP1 Inhibitor OC-3 to Lee’s Pharm in $27 Million Asia Deal https://t.co/HzjGmn5T5A #BioPharmChina #ChinaBioTech #ChinaPharma #PharmaPartnerships

[BioPharmChina @Biopharm_China]

Windward Bio’s WIN378 Delivers Positive Phase 2 Asthma Data as Twice-Yearly Anti-TSLP Antibody Moves Into Phase 3 https://t.co/NVsQHZ4f29 #BioPharmChina #ChinaBioTech #ChinaPharma #Asthma

[BioPharmChina @Biopharm_China]

iRegene’s NouvSight001 Cleared for Retinitis Pigmentosa Trials in China and U.S. https://t.co/93yt7M9Gzr #BioPharmChina #ChinaBioTech #ChinaPharma

[BioPharmChina @Biopharm_China]

Lumiere Therapeutics Raises Over RMB 100 Million to Advance Epigenetic Editing Therapies https://t.co/t9Q1G65MlN #BioPharmChina #ChinaBioTech #ChinaPharma #GeneEditing #GeneTherapy